A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

NCT06568692 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
TNBC - Triple-Negative Breast Cancer
HER2-negative Breast Cancer

Interventions

DRUG: PCS6422 and capecitabine
DRUG: Capecitabine

Sponsor

Processa Pharmaceuticals